Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome - 03/02/23
, Renzhi Pei a, Ying Lu a, ⁎, Zhongzheng Zheng b, Zhiyang Yuan b, Daiyang Li b, Pisheng Zhang a, Xuhui Liu a, Dong Chen a, Xiaohong Du a, Lieguang Chen a, Shuangyue Li a, Peipei Ye a, Tiantian Wang aAbstract |
Introduction |
Relapse and graft-versus-host disease (GVHD) are the important complications influencing mortality for patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). GVHD prophylaxis based on post-transplant cyclophosphamide (PTCy) or antithymocyte globulin (ATG) is widely used in haploidentical HSCT (haplo-HSCT).
Objective |
We developed a modified intensified conditioning regimen including fludarabine (Flu) and investigated the effect of ATG-PTCy combination on transplant outcomes in high-risk AML and MDS compared with those patients who received only ATG as GVHD prophylaxis.
Methods |
A total of 80 patients with high-risk AML and MDS were divided into two groups and assigned to one-to-one pairing.
Results |
The modified ATG-PTCy group had more infused mononuclear cells, CD34-positive cells and CD3-positive cells than those in the ATG group (P < 0.05). The amount of platelet transfusion was higher in the ATG group than the modified ATG-PTCy group [2 (range, 1–6) U vs 2 (range, 1–5) U, P = 0.005]. The median of platelet recovery was better in the modified ATG-PTCy group than in the ATG group (12 days vs 13 days,P = 0.041). The infection rates of bacteria, fungi and virus at 100 days after transplantation were similar in both groups. Compared with the ATG group, individuals who received the modified ATG-PTCy regimen had higher 2-year GVHD- and relapse-free survival(GRFS) [60.0% (95%CI, 44.9–75.1%) vs 34.8% (95%CI, 19.9–49.7%), P = 0.028]; lower 180-day incidence of II-IV acute GVHD (aGVHD) [15.0% (95%CI, 4.0–26.0%) vs 39.8% (95%CI, 23.9–55.7%), P = 0.029]; lower 1-year incidence of moderate to severe chronic GVHD (cGVHD) [2.9% (95%CI, 2.0–3.8%) vs 19.6% (95%CI, 5.3–33.9%), P = 0.039]; and without an increase in the 2-year cumulative incidence of relapse (CIR) [19.5% (95%CI, 6.6–32.4%) vs 30.4% (95%CI, 15.3–45.5%), P = 0.291].
Conclusions |
High-dose stem cells can promote blood cell implantation. The modified ATG-PTCy combination was associated with decreased risk of aGVHD and cGVHD, no increased risk of recurrence, and improved GRFS. It represents an effective strategy for high risk AML and MDS.
Le texte complet de cet article est disponible en PDF.Keywords : Acute myeloid leukemia, Conditioning regimens, Fludarabine, haploidentical allogeneic hematopoietic stem cell transplantation, Post-transplantation cyclophosphamide
Plan
| Source of fund This research was supported in part by the Ningbo and Yinzhou District Social and Development project(2016C51018, and YZ2017-59), Ningbo Public welfare project (2019C50071), China. |
Vol 71 - N° 1
Article 103360- janvier 2023 Retour au numéro
Article précédent
- The fecal microbiota of gravidas with fetal growth restriction newborns characterized by metagenomic sequencing
- Xin He, Zhengpeng Li, Xiaohui Li, Huanying Zhao, Yanan Hu, Wenli Han, Chen Wang, Chenghong Yin, Yi Chen
- APOE ε4 and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO, and acylcarnitines in blood and brain
- Claire J.C. Huguenard, Adam Cseresznye, James E. Evans, Teresa Darcey, Aurore Nkiliza, Andrew P. Keegan, Cheryl Luis, David A. Bennett, Zoe Arvanitakis, Hussein N. Yassine, Michael Mullan, Fiona Crawford, Laila Abdullah
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?